Keyphrases
Lung Disease
100%
Disease Treatment
100%
Disease Outcome
100%
Disease Course
100%
Treatment Strategy
50%
Clinical Status
33%
Clinical Trials
16%
Management Strategy
16%
Multi-domain
16%
Electronic Medical Records
16%
Lung
16%
Clinical Data
16%
Prospective Cohort Study
16%
Optimal Treatment
16%
Change of Measure
16%
Hypoxia
16%
Image Features
16%
Clinical Course
16%
Adverse Reactions
16%
Life-limiting Conditions
16%
Disease Complications
16%
Ventilator Support
16%
Immunosuppressive Therapy
16%
Serum Biomarkers
16%
Disease Activity Score
16%
Macrophage Activation Syndrome
16%
Low Mortality
16%
Interleukin-18 (IL-18)
16%
Clinical Change
16%
Serum Interleukins
16%
Biological Treatment
16%
HLA-DRB1
16%
Direct Therapy
16%
Respiratory Support
16%
Overnight Oximetry
16%
Matrix Metalloproteinase 7 (MMP7)
16%
Biochemistry, Genetics and Molecular Biology
Haplotype
100%
Electronic Medical Record
100%
Clinical Trial
100%
Chemokine
100%
HLA-DRB1
100%
Prospective Cohort Study
100%
Matrilysin
100%
Macrophage Activation
100%
Interleukin 18
100%
Medicine and Dentistry
Silo-Filler's Disease
100%
Disease Course
100%
Biological Product
33%
Biological Marker
16%
Clinical Trial
16%
Adverse Event
16%
Electronic Patient Record
16%
Prospective Cohort Study
16%
Assisted Ventilation
16%
Hypoxia
16%
Macrophage Activation Syndrome
16%
Interleukin 18
16%
Haplotype
16%
Chemokine
16%
Lung
16%
Diseases
16%
Oximetry
16%
HLA-DRB1
16%
Nursing and Health Professions
Lung Disease
100%
Disease Course
100%
Biological Product
33%
Electronic Medical Record
16%
Imaging
16%
Adverse Event
16%
Prospective Cohort Study
16%
Hypoxia
16%
Biological Marker
16%
Interleukin 18
16%
Chemokine
16%
Assisted Ventilation
16%
Oximetry
16%
Diseases
16%
Macrophage Activation Syndrome
16%
Immunology and Microbiology
Biological Product
100%
Haplotype
50%
Electronic Medical Record
50%
Macrophage Activation Syndrome
50%
Interleukin 18
50%
Chemokine
50%
HLA DRB1 Antigen
50%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Disease
100%
Disease Course
100%
Biological Product
33%
Biological Marker
16%
Clinical Trial
16%
Adverse Event
16%
Prospective Cohort Study
16%
Hypoxia
16%
Interleukin 18
16%
Chemokine
16%
Matrilysin
16%
Diseases
16%